Show simple item record

dc.contributor.authorWatkins, L
dc.contributor.authorLinehan, C
dc.contributor.authorBrandt, C
dc.contributor.authorSnoeijen-Schouwenaars, F
dc.contributor.authorMcGowan, P
dc.contributor.authorShankar, Rohit
dc.date.accessioned2021-11-14T20:36:22Z
dc.date.issued2022-02
dc.identifier.issn1294-9361
dc.identifier.issn1950-6945
dc.identifier.urihttp://hdl.handle.net/10026.1/18349
dc.description.abstract

<jats:title>Abstract</jats:title><jats:p>This seminar in epileptology addresses Learning Objective 6.1.4 of the International League against Epilepsy Curriculum: Demonstrate the ability to recognize and manage the special needs of persons with epilepsy (and Neurodevelopmental Disorders [NDDs]). The review identifies the essential competencies for neurologists working with people with epilepsy and NDDs, and these competencies are discussed alongside clinical examples. Furthermore, the seminar explores the opportunities offered by integrated service provision between neurology and services for NDD. The epileptic encephalopathies are not a subject of this seminar paper as they are circumscribed by other ILAE learning objectives. This seminar frames the complexity of seizures in association with NDD with a focus on major NDDs; intellectual disability, autism spectrum disorder, and attention deficit hyperactivity disorder. The evidence presented considers epidemiology, co‐morbidities, risk factors, mortality, and the diagnostic and treatment challenges. People with NDDs and epilepsy have higher rates of physical and psychiatric co‐morbidity, polypharmacy, neuropsychiatric side effects of drugs, and premature mortality including sudden unexpected death in epilepsy. There is a limited Level 1 evidence base to guide assessment and treatment for seizures in adults with NDDs. Therefore, throughout this seminar, the evidence presented for associations and treatment should be observed in context along with its limitations. The evidence for pharmacological treatment of seizures in association with NDDs is presented alongside expert commentary and guidance. There is Level 2 evidence to support treatment with some of the newer anti‐seizure medications including brivaracetam, lacosamide, eslicarbazepine acetate, and perampanel as second‐line choices. Seizures with a co‐morbid NDD should be considered as a collective complex clinical presentation and not discrete conditions. This seminar was co‐designed, co‐produced and co‐authored by an expert by experience and includes case studies and a video to highlight what can go wrong and how it can be avoided.</jats:p>

dc.format.extent9-25
dc.format.mediumPrint
dc.languageen
dc.language.isoen
dc.publisherWiley
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectseizures
dc.subjectintellectual disability
dc.subjectADHD
dc.subjectautism spectrum disorders
dc.subjectcomorbidity
dc.subjectbehavioural health
dc.subjectmental health
dc.subjectphysical health
dc.titleEpilepsy in adults with neurodevelopmental disability - what every neurologist should know
dc.typejournal-article
dc.typeCongress
plymouth.author-urlhttps://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000755300400003&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008
plymouth.issue1
plymouth.volume24
plymouth.publication-statusPublished
plymouth.journalEpileptic Disorders: international epilepsy journal with videotape
dc.identifier.doi10.1684/epd.2021.1366
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Users by role
dc.publisher.placeUnited States
dcterms.dateAccepted2021-11-11
dc.identifier.eissn1950-6945
rioxxterms.versionofrecord10.1684/epd.2021.1366
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International

All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV